WO2008133129A1 - Agent thérapeutique pour le glaucome renfermant un agoniste du récepteur a2a de l'adénosine en tant que principe actif - Google Patents
Agent thérapeutique pour le glaucome renfermant un agoniste du récepteur a2a de l'adénosine en tant que principe actif Download PDFInfo
- Publication number
- WO2008133129A1 WO2008133129A1 PCT/JP2008/057394 JP2008057394W WO2008133129A1 WO 2008133129 A1 WO2008133129 A1 WO 2008133129A1 JP 2008057394 W JP2008057394 W JP 2008057394W WO 2008133129 A1 WO2008133129 A1 WO 2008133129A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- ring
- glaucoma
- adenosine
- therapeutic agent
- Prior art date
Links
- 229940122086 Adenosine A2a receptor agonist Drugs 0.000 title abstract 2
- 208000010412 Glaucoma Diseases 0.000 title abstract 2
- 239000002465 adenosine A2a receptor agonist Substances 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 206010030043 Ocular hypertension Diseases 0.000 abstract 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 230000001077 hypotensive effect Effects 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001425 triazolyl group Chemical group 0.000 abstract 1
- ZOTHAEBAWXWVID-HXEFRTELSA-N uk-432,097 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(C(=O)NCCNC(=O)NC3CCN(CC3)C=3N=CC=CC=3)=NC(NCC(C=3C=CC=CC=3)C=3C=CC=CC=3)=C2N=C1 ZOTHAEBAWXWVID-HXEFRTELSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Ophthalmology & Optometry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
GW-328267, UK-432097 ou un composé représenté par la formule générale (1) ou l'un de ses sels, qui est un agoniste du récepteur A2A de l'adénosine, présente un excellent effet hypotenseur oculaire dans le test sur la diminution de la pression oculaire et il est donc utile en tant qu'agent prophylactique ou thérapeutique pour le glaucome ou l'hypertension oculaire. Dans la formule générale, W représente un atome d'hydrogène ou un groupe représenté par la formule générale (8); le cycle A représente un cycle benzène, un cycle pyridine, un cycle pyrazole, un cycle imidazole, un cycle cyclohexane ou analogues; X représente une liaison simple, O-CH2-CH2, NH-NH=CH, NH-CH2-CH2, CO-NH-CH2 ou analogues; Y représente CH ou N; Z représente CH2 ou O; R1 représente un atome d'hydrogène, un atome d'halogène, un groupe alkyle, un groupe alkylaminocarbonyle ou analogues; R2 représente un groupe hydroxyalkyle, un groupe alkylamino, un groupe alkylaminocarbonyle, un groupe triazolyle ou analogues; et R3 représente un atome d'hydrogène, un groupe alkyle ou analogues.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2007-106917 | 2007-04-16 | ||
| JP2007106917 | 2007-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2008133129A1 true WO2008133129A1 (fr) | 2008-11-06 |
Family
ID=39925585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2008/057394 WO2008133129A1 (fr) | 2007-04-16 | 2008-04-16 | Agent thérapeutique pour le glaucome renfermant un agoniste du récepteur a2a de l'adénosine en tant que principe actif |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP2008285478A (fr) |
| WO (1) | WO2008133129A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010524933A (ja) * | 2007-04-16 | 2010-07-22 | 参天製薬株式会社 | アデノシン誘導体を有効成分として含有する緑内障治療剤 |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020253866A1 (fr) * | 2019-06-21 | 2020-12-24 | 中国人民解放军军事科学院军事医学研究院 | Composé d'adénosine, sel pharmaceutiquement acceptable ou stéréoisomère associé, et utilisation |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06128281A (ja) * | 1992-04-24 | 1994-05-10 | Whitby Res Inc | ヒドラゾアデノシン類 |
| WO2000012098A1 (fr) * | 1998-09-01 | 2000-03-09 | Yamasa Corporation | Compositions medicinales pour le traitement des maladies oculaires |
| JP2002518510A (ja) * | 1998-06-23 | 2002-06-25 | グラクソ グループ リミテッド | ２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体 |
| JP2003506461A (ja) * | 1999-06-22 | 2003-02-18 | スィーヴィー セラピューティクス インコーポレイテッド | Ｎ−ピラゾールａ２ａ受容体アゴニスト |
| JP2004508284A (ja) * | 2000-02-18 | 2004-03-18 | ファイザー・インク | プリン誘導体 |
-
2008
- 2008-04-16 WO PCT/JP2008/057394 patent/WO2008133129A1/fr active Application Filing
- 2008-04-16 JP JP2008106283A patent/JP2008285478A/ja not_active Withdrawn
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06128281A (ja) * | 1992-04-24 | 1994-05-10 | Whitby Res Inc | ヒドラゾアデノシン類 |
| JP2002518510A (ja) * | 1998-06-23 | 2002-06-25 | グラクソ グループ リミテッド | ２−（プリン−９−イル）−テトラヒドロフラン−３，４−ジオール誘導体 |
| WO2000012098A1 (fr) * | 1998-09-01 | 2000-03-09 | Yamasa Corporation | Compositions medicinales pour le traitement des maladies oculaires |
| JP2002173427A (ja) * | 1998-09-01 | 2002-06-21 | Yamasa Shoyu Co Ltd | 眼疾患治療用医薬組成物 |
| JP2003506461A (ja) * | 1999-06-22 | 2003-02-18 | スィーヴィー セラピューティクス インコーポレイテッド | Ｎ−ピラゾールａ２ａ受容体アゴニスト |
| JP2004508284A (ja) * | 2000-02-18 | 2004-03-18 | ファイザー・インク | プリン誘導体 |
Non-Patent Citations (3)
| Title |
|---|
| KONNO T. ET AL.: "Effect of 2-(6-cyano-1-hexyn-1-yl)adenosine on ocular blood flow in rabbits", LIFE SCIENCE, vol. 80, no. 12, February 2007 (2007-02-01), pages 1115 - 1122, XP005891969 * |
| KONNO T.: "Role of adenosine in intraocular pressure", NIPPON YAKURIGAKU ZASSHI, vol. 123, no. 4, 2004, pages 289 - 294 * |
| MASAYUKI U. ET AL.: "2-Aralkoxyadenosines: potent and selective agonists at the coronary artery A2 adenosine receptor", J. MED. CHEM., vol. 34, 1991, pages 1340 - 1344, XP002961133, DOI: doi:10.1021/jm00108a015 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010524933A (ja) * | 2007-04-16 | 2010-07-22 | 参天製薬株式会社 | アデノシン誘導体を有効成分として含有する緑内障治療剤 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008285478A (ja) | 2008-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005080384A3 (fr) | Dérivé du benzimidazole et ses utilisations | |
| WO2005075458A8 (fr) | Derives de pyrimidine utilises en tant qu'antagonistes de recepteurs d'orexine | |
| MX2009013626A (es) | DERIVADO DE 17ß-CIANO-18A-HOMO-19-NOR-ANDROST-4-ENO, SU USO Y MEDICAMENTO QUE LO CONTIENE. | |
| WO2008006043A3 (fr) | Dérivés d'acide substitués pouvant être employés en tant qu'agents anti-athérosclérotiques, anti-dyslipidémiques, anti-diabétiques et anti-obésité, et méthode | |
| WO2002076950A3 (fr) | Procede et composes de traitement presentant une activite selective similaire a celle d'agonistes des recepteurs adrenergiques alpha 2b ou 2b/2c | |
| WO2008096829A1 (fr) | Composés tricycliques | |
| NO20060154L (no) | Imidazolyl-derivater | |
| WO2009072621A1 (fr) | Composé dihydroazole substitué et agent antiparasitaire | |
| NO20051411L (no) | Pyrazolderivater, medisinske sammensetninger inneholdende slike, medisinsk bruk derav samt intermediater til fremstilling derav | |
| MY141559A (en) | Triazole derivatives as tachykinin receptor antagonists | |
| ATE388958T1 (de) | 4'-c-substituierte 2-haloadenosinderivate | |
| TW200738667A (en) | Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof | |
| WO2009035067A1 (fr) | Agonistes des récepteurs des glucocorticoïdes constitués de dérivés de la 1,3,3-triméthyle-7-phényle-3,4-dihydro-1h-quinoxaline-2-one | |
| RS51674B (en) | PIPERIDIN-4-IL-PIRIDAZIN-3-ILAMINE DERIVATIVES AS A FAST DISSOCATING DOPAMIN 2 RECEIVER ANTAGONISTS | |
| WO2009038064A1 (fr) | Dérivé hétérocyclique à activité inhibitrice sur la 11β-hydroxystéroïde déshydrogénase de type i | |
| EP1854789A4 (fr) | Derive de quinazoline possedant une activite inhibitrice vis-a-vis de la tyrosine kinase | |
| WO2007017728A3 (fr) | Nouveaux composes heterocycliques | |
| WO2009095792A3 (fr) | Dérivés d'hétéroarylamide diazépinopyrimidone substitués | |
| NO20072753L (no) | 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer | |
| MX2009011076A (es) | Agente terapeutico para glaucoma que contiene derivado de adenosina como ingrediente activo. | |
| WO2007144512A3 (fr) | Derivés diazeniumdiolates, leur procédé de préparation, leurs compositions pharmaceutiques et leur utilisation dans le domaine de l ' hypertension et des pathologies cardiovasculaires | |
| NZ552137A (en) | New 4-benzylidene-piperidin derivatives | |
| TW200606152A (en) | Piperidine compound and process for preparing the same | |
| WO2008149834A1 (fr) | Dérivé de pyrimidodiazépinone | |
| RS52518B (en) | 4-ALCOXYPYRIDASINE DERIVATIVES AS A FAST DISSOCATING DOPAMINE 2 RECEPTOR ANTAGONISTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08740475 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08740475 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |